Novavax is a biotechnology company committed to help address serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Resources prepared for you to answer your questions

Global authorization site of Novavax COVID-19 Vaccine (recombinant, adjuvanted)

Product summary for healthcare professionals, patient information, expiry date checker, FAQs, and more

Global medical information site

Ask medical questions, report adverse events, and report product quality complaints


Source in-depth information including clinical trial protocols of our research areas

PREVENT-19 fact sheet

Review the summary of PREVENT-19, a phase 3, randomized, observer-blinded, placebo-controlled trial evaluation of NVX-CoV2373 vaccine efficacy, immunogenicity, and safety in adults 18 and older.

Investigator-Initiated Studies (IIS)

The Novavax IIS program supports clinical and non-clinical research that addresses important unmet scientific or medical needs aligned with Novavax's areas of interest. Support for an approved IIS may include funding, Novavax product, or both.

Become a clinical trial site with Novavax

If you are interested in participating as a clinical trial site with Novavax, please complete the site questionnaire.

Science & technology

Novavax COVID-19 Vaccine is now conditionally authorized in several regions.

Science & technology

Recombinant nanoparticle vaccine technology

Science & technology

Matrix-M™ adjuvant technology

Science & technology

Our pipeline—creating tomorrow's vaccine today

Want to learn more about our vaccines?

green graphic image